Literature DB >> 25773782

Generation of antigen-specific Foxp3+ regulatory T-cells in vivo following administration of diabetes-reversing tolerogenic microspheres does not require provision of antigen in the formulation.

Carl Engman1, Yi Wen2, Wilson S Meng3, Rita Bottino4, Massimo Trucco5, Nick Giannoukakis6.   

Abstract

We have developed novel antisense oligonucleotide-formulated microspheres that can reverse hyperglycemia in newly-onset diabetic mice. Dendritic cells taking up the microspheres adopt a restrained co-stimulation ability and migrate to the pancreatic lymph nodes when injected into an abdominal region that is drained by those lymph nodes. Furthermore, we demonstrate that the absolute numbers of antigen-specific Foxp3+ T regulatory cells are increased only in the lymph nodes draining the site of administration and that these T-cells proliferate independently of antigen supply in the microspheres. Taken together, our data add to the emerging model where antigen supply may not be a requirement in "vaccines" for autoimmune disease, but the site of administration - subserved by lymph nodes draining the target organ - is in fact critical to foster the generation of antigen-specific regulatory cells. The implications of these observations on "vaccine" design for autoimmunity are discussed and summarized.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antigen; Dendritic; Diabetes; Immunotherapy; Microspheres; Tolerogenic

Mesh:

Substances:

Year:  2015        PMID: 25773782     DOI: 10.1016/j.clim.2015.03.004

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  16 in total

Review 1.  Auto-antigen and Immunomodulatory Agent-Based Approaches for Antigen-Specific Tolerance in NOD Mice.

Authors:  Ethan J Bassin; Jon D Piganelli; Steven R Little
Journal:  Curr Diab Rep       Date:  2021-02-06       Impact factor: 4.810

Review 2.  Immune Tolerance for Autoimmune Disease and Cell Transplantation.

Authors:  Xunrong Luo; Stephen D Miller; Lonnie D Shea
Journal:  Annu Rev Biomed Eng       Date:  2016-02-24       Impact factor: 9.590

Review 3.  Combinatorial drug delivery approaches for immunomodulation.

Authors:  Joshua M Stewart; Benjamin G Keselowsky
Journal:  Adv Drug Deliv Rev       Date:  2017-05-19       Impact factor: 15.470

4.  Engineering immunomodulatory biomaterials for type 1 diabetes.

Authors:  C L Stabler; Y Li; J M Stewart; B G Keselowsky
Journal:  Nat Rev Mater       Date:  2019-05-17       Impact factor: 66.308

5.  Immature Dendritic Cell Therapy Confers Durable Immune Modulation in an Antigen-Dependent and Antigen-Independent Manner in Nonobese Diabetic Mice.

Authors:  Jeannette Lo; Chang-Qing Xia; Ruihua Peng; Michael J Clare-Salzler
Journal:  J Immunol Res       Date:  2018-02-14       Impact factor: 4.818

Review 6.  Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance.

Authors:  Takashi Kei Kishimoto; Roberto A Maldonado
Journal:  Front Immunol       Date:  2018-02-20       Impact factor: 7.561

Review 7.  Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases.

Authors:  David A Horwitz; Sean Bickerton; Antonio La Cava
Journal:  Front Immunol       Date:  2021-06-15       Impact factor: 7.561

8.  Salt-Dependent Aggregation and Assembly of E coli-Expressed Ferritin.

Authors:  Wei Sun; Chengfeng Jiao; Yue Xiao; Luowei Wang; Cheng Yu; Jialin Liu; Yongli Yu; Liying Wang
Journal:  Dose Response       Date:  2016-02-26       Impact factor: 2.658

Review 9.  Advances in drug delivery system for platinum agents based combination therapy.

Authors:  Xiang Kang; Hai-Hua Xiao; Hai-Qin Song; Xia-Bin Jing; Le-San Yan; Ruo-Gu Qi
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

10.  Local retention of antibodies in vivo with an injectable film embedded with a fluorogen-activating protein.

Authors:  Wen Liu; Matthew J Saunders; Christina Bagia; Eric C Freeman; Yong Fan; Ellen S Gawalt; Alan S Waggoner; Wilson S Meng
Journal:  J Control Release       Date:  2016-03-31       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.